Prognostic Analysis of Hormone Receptors and HER2 in Breast Squamous Cell Carcinoma: A Matched Study Using the SEER Database

To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype. We extracted data from the SEER Registry for adult women diagnosed with BSCC and BIDC from 2010 to 2020. Kaplan-Meier curves and log-rank te...

Full description

Saved in:
Bibliographic Details
Published inClinical breast cancer Vol. 25; no. 6; pp. e739 - e749.e2
Main Authors Wang, Miao, Hu, Kehua, Gao, Yanping, Guo, Xiaowan, Li, Jie, Xia, Yaoxiong, Qiu, Hui, Wu, Qiuji
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.08.2025
Subjects
Online AccessGet full text

Cover

Loading…
Abstract To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype. We extracted data from the SEER Registry for adult women diagnosed with BSCC and BIDC from 2010 to 2020. Kaplan-Meier curves and log-rank tests assessed survival differences. Propensity score matching analysis (PSM) was used to match subjects with similar characteristics. Cox proportional hazard regression models identified survival predictors. BSCC patients were older (> 60 years: 60.6% vs. 52.4%, P = .037), had higher TNBC incidence (64.0% vs. 12.2%, P = .001), and higher metastasis rates (48% vs. 33.3%, P < .001) compared to BIDC. Marriage rate was lower in BSCC patients (44.6% vs. 54.9%, P = .009). BSCC patients had worse OS and CSS (P < .001). In non-TNBC, BSCC showed poor survival before and after PSM (P < .05). In TNBC, BSCC had worse OS than BIDC (P < .001), but similar CSS before PSM. After PSM, no survival difference was observed. Stage was a significant prognostic factor for BSCC (P < .001), while receptor subtype was not (P > .05). BSCC has a higher TNBC incidence and poorer survival in non-TNBC populations compared to BIDC. BSCC-TNBC patients have similar survival to BIDC-TNBC. Stage is a crucial prognostic factor for BSCC, more so than receptor subtype. This study compared prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) based on receptor subtypes using SEER registry data. Receptor subtype-based stratified survival analyses demonstrated that BSCC had a poorer survival in non-TNBC populations compared to BIDC, while BSCC-TNBC patients had similar survival to BIDC-TNBC. Notably, stage is a crucial prognostic factor for BSCC, more so than receptor subtype. These findings highlight that BSCC represents a highly aggressive malignancy, suggesting increased clinical attention in treatment strategies.
AbstractList To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype.OBJECTIVETo determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype.We extracted data from the SEER Registry for adult women diagnosed with BSCC and BIDC from 2010 to 2020. Kaplan-Meier curves and log-rank tests assessed survival differences. Propensity score matching analysis (PSM) was used to match subjects with similar characteristics. Cox proportional hazard regression models identified survival predictors.MATERIALS AND METHODSWe extracted data from the SEER Registry for adult women diagnosed with BSCC and BIDC from 2010 to 2020. Kaplan-Meier curves and log-rank tests assessed survival differences. Propensity score matching analysis (PSM) was used to match subjects with similar characteristics. Cox proportional hazard regression models identified survival predictors.BSCC patients were older (> 60 years: 60.6% vs. 52.4%, P = .037), had higher TNBC incidence (64.0% vs. 12.2%, P = .001), and higher metastasis rates (48% vs. 33.3%, P < .001) compared to BIDC. Marriage rate was lower in BSCC patients (44.6% vs. 54.9%, P = .009). BSCC patients had worse OS and CSS (P < .001). In non-TNBC, BSCC showed poor survival before and after PSM (P < .05). In TNBC, BSCC had worse OS than BIDC (P < .001), but similar CSS before PSM. After PSM, no survival difference was observed. Stage was a significant prognostic factor for BSCC (P < .001), while receptor subtype was not (P > .05).RESULTSBSCC patients were older (> 60 years: 60.6% vs. 52.4%, P = .037), had higher TNBC incidence (64.0% vs. 12.2%, P = .001), and higher metastasis rates (48% vs. 33.3%, P < .001) compared to BIDC. Marriage rate was lower in BSCC patients (44.6% vs. 54.9%, P = .009). BSCC patients had worse OS and CSS (P < .001). In non-TNBC, BSCC showed poor survival before and after PSM (P < .05). In TNBC, BSCC had worse OS than BIDC (P < .001), but similar CSS before PSM. After PSM, no survival difference was observed. Stage was a significant prognostic factor for BSCC (P < .001), while receptor subtype was not (P > .05).BSCC has a higher TNBC incidence and poorer survival in non-TNBC populations compared to BIDC. BSCC-TNBC patients have similar survival to BIDC-TNBC. Stage is a crucial prognostic factor for BSCC, more so than receptor subtype.CONCLUSIONBSCC has a higher TNBC incidence and poorer survival in non-TNBC populations compared to BIDC. BSCC-TNBC patients have similar survival to BIDC-TNBC. Stage is a crucial prognostic factor for BSCC, more so than receptor subtype.
To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype. We extracted data from the SEER Registry for adult women diagnosed with BSCC and BIDC from 2010 to 2020. Kaplan-Meier curves and log-rank tests assessed survival differences. Propensity score matching analysis (PSM) was used to match subjects with similar characteristics. Cox proportional hazard regression models identified survival predictors. BSCC patients were older (> 60 years: 60.6% vs. 52.4%, P = .037), had higher TNBC incidence (64.0% vs. 12.2%, P = .001), and higher metastasis rates (48% vs. 33.3%, P < .001) compared to BIDC. Marriage rate was lower in BSCC patients (44.6% vs. 54.9%, P = .009). BSCC patients had worse OS and CSS (P < .001). In non-TNBC, BSCC showed poor survival before and after PSM (P < .05). In TNBC, BSCC had worse OS than BIDC (P < .001), but similar CSS before PSM. After PSM, no survival difference was observed. Stage was a significant prognostic factor for BSCC (P < .001), while receptor subtype was not (P > .05). BSCC has a higher TNBC incidence and poorer survival in non-TNBC populations compared to BIDC. BSCC-TNBC patients have similar survival to BIDC-TNBC. Stage is a crucial prognostic factor for BSCC, more so than receptor subtype. This study compared prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) based on receptor subtypes using SEER registry data. Receptor subtype-based stratified survival analyses demonstrated that BSCC had a poorer survival in non-TNBC populations compared to BIDC, while BSCC-TNBC patients had similar survival to BIDC-TNBC. Notably, stage is a crucial prognostic factor for BSCC, more so than receptor subtype. These findings highlight that BSCC represents a highly aggressive malignancy, suggesting increased clinical attention in treatment strategies.
To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype. We extracted data from the SEER Registry for adult women diagnosed with BSCC and BIDC from 2010 to 2020. Kaplan-Meier curves and log-rank tests assessed survival differences. Propensity score matching analysis (PSM) was used to match subjects with similar characteristics. Cox proportional hazard regression models identified survival predictors. BSCC patients were older (> 60 years: 60.6% vs. 52.4%, P = .037), had higher TNBC incidence (64.0% vs. 12.2%, P = .001), and higher metastasis rates (48% vs. 33.3%, P < .001) compared to BIDC. Marriage rate was lower in BSCC patients (44.6% vs. 54.9%, P = .009). BSCC patients had worse OS and CSS (P < .001). In non-TNBC, BSCC showed poor survival before and after PSM (P < .05). In TNBC, BSCC had worse OS than BIDC (P < .001), but similar CSS before PSM. After PSM, no survival difference was observed. Stage was a significant prognostic factor for BSCC (P < .001), while receptor subtype was not (P > .05). BSCC has a higher TNBC incidence and poorer survival in non-TNBC populations compared to BIDC. BSCC-TNBC patients have similar survival to BIDC-TNBC. Stage is a crucial prognostic factor for BSCC, more so than receptor subtype.
Author Wang, Miao
Xia, Yaoxiong
Wu, Qiuji
Guo, Xiaowan
Li, Jie
Qiu, Hui
Hu, Kehua
Gao, Yanping
Author_xml – sequence: 1
  givenname: Miao
  surname: Wang
  fullname: Wang, Miao
  organization: Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan, Kunming, China
– sequence: 2
  givenname: Kehua
  surname: Hu
  fullname: Hu, Kehua
  organization: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan, China
– sequence: 3
  givenname: Yanping
  surname: Gao
  fullname: Gao, Yanping
  organization: Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan, Kunming, China
– sequence: 4
  givenname: Xiaowan
  surname: Guo
  fullname: Guo, Xiaowan
  organization: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan, China
– sequence: 5
  givenname: Jie
  surname: Li
  fullname: Li, Jie
  organization: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan, China
– sequence: 6
  givenname: Yaoxiong
  surname: Xia
  fullname: Xia, Yaoxiong
  email: 55490850@qq.com
  organization: Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan, Kunming, China
– sequence: 7
  givenname: Hui
  surname: Qiu
  fullname: Qiu, Hui
  email: qiuhuiznyy@whu.edu.cn
  organization: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan, China
– sequence: 8
  givenname: Qiuji
  orcidid: 0000-0002-4655-3108
  surname: Wu
  fullname: Wu, Qiuji
  email: wuqiuji@126.com
  organization: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40450500$$D View this record in MEDLINE/PubMed
BookMark eNqFkU2P0zAQhi20iP2AP8AB-cilwZ9Js-JSSqFIi0Ate7YmzmTXJbG7doJUiR-Pqy4cOIBkaXx4Hntm3kty5oNHQl5yVnDGyze7wvaNLQQTumCqYFw_IRe8lvMZK8vyLN-1KGdzwepzcpnSjjFRSs6ekXPFlGaasQvy82sMdz6k0Vm68NAfkks0dHQd4pB_oxu0uB9DTBR8S9erjaDO03cRIY10-zDBEKZEl9j3dAnROh8GuKYL-hlGe48t3Y5Te6C3yfk7Ot4j3a5WG_oeRmgg4XPytIM-4YvHekVuP6y-Ldezmy8fPy0XNzMrKj3OJHQVMKlBSW6Vbite11rn01XScrBS1V0tG5XHK-vGAjZ1JUrgSlihoBLyirw-vbuP4WHCNJrBJZt7Bo-5fSMF1_VcyEpl9NUjOjUDtmYf3QDxYH5vLAPiBNgYUorY_UE4M8dYzM4cYzHHWAxTJseSpbcnCfOUPxxGk6xDb7F1Ee1o2uD-rV__pdveeWeh_46H_8m_AF5Oprs
Cites_doi 10.1200/JCO.2004.00.9589
10.1200/JCO.2023.41.16_suppl.561
10.1097/PAS.0b013e3182877569
10.1007/BF02305666
10.1186/s12885-018-5212-x
10.1016/S1470-2045(19)30689-8
10.1007/s10549-017-4251-3
10.1016/j.humpath.2017.07.011
10.1002/jso.2930590313
10.1053/ejso.2002.1422
10.1007/s10549-014-3224-z
10.1056/NEJMoa053422
10.1016/j.critrevonc.2021.103223
10.1007/s12282-017-0768-x
10.1056/NEJMoa0802656
10.1007/s10549-020-05525-5
10.1016/j.jogoh.2018.06.007
10.1016/j.prp.2006.01.006
10.18632/oncotarget.7222
10.1177/000313480907501010
10.4103/jcrt.JCRT_303_17
10.1007/s12032-014-0172-8
10.1007/s00595-009-4276-2
10.1056/NEJMoa1809615
ContentType Journal Article
Copyright 2025 Elsevier Inc.
Copyright © 2025 Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2025 Elsevier Inc.
– notice: Copyright © 2025 Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.clbc.2025.04.015
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1938-0666
EndPage e749.e2
ExternalDocumentID 40450500
10_1016_j_clbc_2025_04_015
S1526820925001065
Genre Journal Article
GroupedDBID ---
--K
--M
.1-
.FO
.XZ
.~1
0R~
1P~
1~.
29B
4.4
457
4G.
53G
5GY
6J9
6PF
7-5
8P~
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQQT
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYWO
ABBQC
ABJNI
ABMAC
ABMZM
ABWVN
ABXDB
ACDAQ
ACGFS
ACIEU
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
AEBSH
AEGXH
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGYEJ
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
C45
CAG
COF
DU5
EBD
EBS
EFJIC
EFKBS
EJD
EMB
EMOBN
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
GBLVA
HVGLF
HZ~
KOM
M41
MET
MO0
O-L
O9-
OAUVE
OBH
OC~
OHH
OO-
OVD
P-8
P-9
PC.
Q38
R2-
ROL
SDF
SEL
SES
SPCBC
SSH
SSZ
SV3
T5K
TEORI
UDS
Z5R
~G-
AAYXX
AFCTW
AGRNS
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c275t-3af7a035a431c45d719955955f73c1ac349f93b402669bcaeb9726a142c24a723
IEDL.DBID .~1
ISSN 1526-8209
1938-0666
IngestDate Wed Jul 02 02:48:43 EDT 2025
Mon Jul 21 02:03:52 EDT 2025
Thu Jul 24 02:18:59 EDT 2025
Sat Aug 16 17:00:56 EDT 2025
Tue Aug 26 16:32:32 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Propensity score matching
Breast cancer
Prognosis
Rare tumor
Receptor subtype
Language English
License Copyright © 2025 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c275t-3af7a035a431c45d719955955f73c1ac349f93b402669bcaeb9726a142c24a723
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-4655-3108
PMID 40450500
PQID 3215982374
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3215982374
pubmed_primary_40450500
crossref_primary_10_1016_j_clbc_2025_04_015
elsevier_sciencedirect_doi_10_1016_j_clbc_2025_04_015
elsevier_clinicalkey_doi_10_1016_j_clbc_2025_04_015
PublicationCentury 2000
PublicationDate 2025-08-01
PublicationDateYYYYMMDD 2025-08-01
PublicationDate_xml – month: 08
  year: 2025
  text: 2025-08-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Clinical breast cancer
PublicationTitleAlternate Clin Breast Cancer
PublicationYear 2025
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Schmid, Rugo, Adams (bib0028) 2020; 21
Oikawa, Igawa, Taguchi (bib0016) 2017; 24
Wu, Sun, Liu, Li, Lin, He (bib0010) 2016; 7
Benoist, Mureau, Joueidi (bib0019) 2018; 47
Hennessy, Krishnamurthy, Giordano (bib0011) 2005; 23
Stevenson, Graham, Khiyami, Mansour (bib0020) 1996; 3
Pirot, Chaltiel, Ben Lakhdar, Mathieu, Rimareix, Conversano (bib0007) 2020; 180
Ahmed, Idriss, Heiba, Sidi (bib0005) 2019; 33
Tavassoli (bib0003) 2003; 4
Chatha, Bano, Farooq, Farooq, Farooq, Zakaullah (bib0006) 2018; 28
Zhou, Chaudhry, Shah, Andrews (bib0014) 2018; 10
Grabowski, Saltzstein, Sadler, Blair (bib0017) 2009; 75
Liu, Yu, Sun (bib0022) 2015; 149
Honda, Saji, Horiguchi (bib0008) 2011; 41
Cao, Yue, Zhou (bib0024) 2019; 98
Schmid, Adams, Rugo (bib0027) 2018; 379
Behranwala, Nasiri, Abdullah, Trott, Gui (bib0018) 2003; 29
Bonner, Harari, Giralt (bib0025) 2006; 354
Zhu, Chen (bib0009) 2019; 19
Gupta, Malani, Weigand, Rangineni (bib0001) 2006; 202
Wang, Zhang, He (bib0023) 2014; 31
Vermorken, Mesia, Rivera (bib0026) 2008; 359
Dejager, Redlich, Dayer, Davis, Komorowski (bib0021) 1995; 59
Olsen, Keeney, Chen, Visscher, Carter (bib0013) 2017; 67
Soliman (bib0004) 2019; 15
Nayak, Wu, Gilcrease (bib0015) 2013; 37
Yadav, Yadav, Zakalik (bib0002) 2017; 164
Tarantino, Gandini, Trapani, Criscitiello, Curigliano (bib0029) 2021; 159
Ogita, Kubo, Kumamaru (bib0012) 2023; 41
Ahmed (10.1016/j.clbc.2025.04.015_bib0005) 2019; 33
Tavassoli (10.1016/j.clbc.2025.04.015_bib0003) 2003; 4
Nayak (10.1016/j.clbc.2025.04.015_bib0015) 2013; 37
Olsen (10.1016/j.clbc.2025.04.015_bib0013) 2017; 67
Cao (10.1016/j.clbc.2025.04.015_bib0024) 2019; 98
Schmid (10.1016/j.clbc.2025.04.015_bib0028) 2020; 21
Pirot (10.1016/j.clbc.2025.04.015_bib0007) 2020; 180
Zhu (10.1016/j.clbc.2025.04.015_bib0009) 2019; 19
Gupta (10.1016/j.clbc.2025.04.015_bib0001) 2006; 202
Zhou (10.1016/j.clbc.2025.04.015_bib0014) 2018; 10
Oikawa (10.1016/j.clbc.2025.04.015_bib0016) 2017; 24
Behranwala (10.1016/j.clbc.2025.04.015_bib0018) 2003; 29
Soliman (10.1016/j.clbc.2025.04.015_bib0004) 2019; 15
Honda (10.1016/j.clbc.2025.04.015_bib0008) 2011; 41
Bonner (10.1016/j.clbc.2025.04.015_bib0025) 2006; 354
Yadav (10.1016/j.clbc.2025.04.015_bib0002) 2017; 164
Hennessy (10.1016/j.clbc.2025.04.015_bib0011) 2005; 23
Wu (10.1016/j.clbc.2025.04.015_bib0010) 2016; 7
Liu (10.1016/j.clbc.2025.04.015_bib0022) 2015; 149
Dejager (10.1016/j.clbc.2025.04.015_bib0021) 1995; 59
Ogita (10.1016/j.clbc.2025.04.015_bib0012) 2023; 41
Wang (10.1016/j.clbc.2025.04.015_bib0023) 2014; 31
Stevenson (10.1016/j.clbc.2025.04.015_bib0020) 1996; 3
Benoist (10.1016/j.clbc.2025.04.015_bib0019) 2018; 47
Vermorken (10.1016/j.clbc.2025.04.015_bib0026) 2008; 359
Tarantino (10.1016/j.clbc.2025.04.015_bib0029) 2021; 159
Schmid (10.1016/j.clbc.2025.04.015_bib0027) 2018; 379
Chatha (10.1016/j.clbc.2025.04.015_bib0006) 2018; 28
Grabowski (10.1016/j.clbc.2025.04.015_bib0017) 2009; 75
References_xml – volume: 149
  start-page: 133
  year: 2015
  end-page: 140
  ident: bib0022
  article-title: Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast
  publication-title: Breast Cancer Res Treat
– volume: 4
  start-page: 100
  year: 2003
  end-page: 103
  ident: bib0003
  article-title: WHO classification of tumors. Tumors of the breast and female genital organs
  publication-title: Lyon IRAC
– volume: 7
  start-page: 10684
  year: 2016
  end-page: 10693
  ident: bib0010
  article-title: Effect of postoperative radiotherapy for squamous cell cancer of the breast in a surveillance epidemiology and end results population-based study
  publication-title: Oncotarget
– volume: 10
  start-page: e3405
  year: 2018
  ident: bib0014
  article-title: Breast squamous cell carcinoma following breast augmentation
  publication-title: Cureus
– volume: 21
  start-page: 44
  year: 2020
  end-page: 59
  ident: bib0028
  article-title: Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet Oncol
– volume: 19
  start-page: 26
  year: 2019
  ident: bib0009
  article-title: Clinicopathological features, treatment patterns, and prognosis of squamous cell carcinoma of the breast: an NCDB analysis
  publication-title: BMC Cancer
– volume: 202
  start-page: 465
  year: 2006
  end-page: 469
  ident: bib0001
  article-title: Pure primary squamous cell carcinoma of the breast: a rare presentation and clinicopathologic comparison with usual ductal carcinoma of the breast
  publication-title: Pathol Res Pract
– volume: 67
  start-page: 94
  year: 2017
  end-page: 100
  ident: bib0013
  article-title: Breast implant capsule-associated squamous cell carcinoma: a report of 2 cases
  publication-title: Hum Pathol
– volume: 359
  start-page: 1116
  year: 2008
  end-page: 1127
  ident: bib0026
  article-title: Platinum-based chemotherapy plus cetuximab in head and neck cancer
  publication-title: N Engl J Med
– volume: 379
  start-page: 2108
  year: 2018
  end-page: 2121
  ident: bib0027
  article-title: Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer
  publication-title: N Engl J Med
– volume: 24
  start-page: 733
  year: 2017
  end-page: 741
  ident: bib0016
  article-title: Cytogenetic analysis of metaplastic squamous cell carcinoma of the breast inter- and intratumoral heterogeneity
  publication-title: Breast Cancer
– volume: 47
  start-page: 275
  year: 2018
  end-page: 280
  ident: bib0019
  article-title: Management and prognosis of pure primary squamous cell carcinoma of the breast
  publication-title: J Gynecol Obstet Hum Reprod
– volume: 28
  start-page: 776
  year: 2018
  end-page: 778
  ident: bib0006
  article-title: Squamous cell carcinoma of the breast
  publication-title: J Coll Physicians Surg Pak
– volume: 41
  start-page: 561
  year: 2023
  ident: bib0012
  article-title: Prognosis of squamous cell carcinoma of the breast by biological subtypes and the efficacy of radiotherapy: the Japanese breast cancer registry analysis
  publication-title: Journal of Clinical Oncology
– volume: 164
  start-page: 201
  year: 2017
  end-page: 208
  ident: bib0002
  article-title: Squamous cell carcinoma of the breast in the United States: incidence, demographics, tumor characteristics, and survival
  publication-title: Breast Cancer Res Treat
– volume: 23
  start-page: 7827
  year: 2005
  end-page: 7835
  ident: bib0011
  article-title: Squamous cell carcinoma of the breast
  publication-title: J Clin Oncol
– volume: 31
  start-page: 172
  year: 2014
  ident: bib0023
  article-title: Co-expression of EGFR and CK5/6 in primary squamous cell carcinoma of the breast
  publication-title: Med Oncol
– volume: 59
  start-page: 199
  year: 1995
  end-page: 203
  ident: bib0021
  article-title: Primary squamous cell carcinoma of the breast: sensitivity to cisplatinum-based chemotherapy
  publication-title: J Surg Oncol
– volume: 41
  start-page: 328
  year: 2011
  end-page: 332
  ident: bib0008
  article-title: Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast
  publication-title: Surg Today
– volume: 37
  start-page: 867
  year: 2013
  end-page: 873
  ident: bib0015
  article-title: Primary squamous cell carcinoma of the breast: predictors of locoregional recurrence and overall survival
  publication-title: Am J Surg Pathol
– volume: 354
  start-page: 567
  year: 2006
  end-page: 578
  ident: bib0025
  article-title: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
  publication-title: N Engl J Med
– volume: 15
  start-page: 1057
  year: 2019
  end-page: 1061
  ident: bib0004
  article-title: Squamous cell carcinoma of the breast: a retrospective study
  publication-title: J Cancer Res Ther
– volume: 180
  start-page: 87
  year: 2020
  end-page: 95
  ident: bib0007
  article-title: Squamous cell carcinoma of the breast, are there two entities with distinct prognosis? a series of 39 patients
  publication-title: Breast Cancer Res Treat
– volume: 75
  start-page: 914
  year: 2009
  end-page: 917
  ident: bib0017
  article-title: Squamous cell carcinoma of the breast: a review of 177 cases
  publication-title: Am Surg
– volume: 33
  start-page: 143
  year: 2019
  ident: bib0005
  article-title: [Squamous cell carcinoma of the breast: a case study conducted in Mauritania]
  publication-title: Pan Afr Med J
– volume: 29
  start-page: 386
  year: 2003
  end-page: 389
  ident: bib0018
  article-title: Squamous cell carcinoma of the breast: clinico-pathologic implications and outcome
  publication-title: Eur J Surg Oncol
– volume: 3
  start-page: 367
  year: 1996
  end-page: 374
  ident: bib0020
  article-title: Squamous cell carcinoma of the breast: a clinical approach
  publication-title: Ann Surg Oncol
– volume: 98
  year: 2019
  ident: bib0024
  article-title: Change of HER2 status during disease recurrence predicts good prognosis for primary squamous cell carcinoma of the breast: a case report
  publication-title: Medicine (Baltimore)
– volume: 159
  year: 2021
  ident: bib0029
  article-title: Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials
  publication-title: Crit Rev Oncol Hematol
– volume: 4
  start-page: 100
  year: 2003
  ident: 10.1016/j.clbc.2025.04.015_bib0003
  article-title: WHO classification of tumors. Tumors of the breast and female genital organs
  publication-title: Lyon IRAC
– volume: 23
  start-page: 7827
  year: 2005
  ident: 10.1016/j.clbc.2025.04.015_bib0011
  article-title: Squamous cell carcinoma of the breast
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2004.00.9589
– volume: 41
  start-page: 561
  year: 2023
  ident: 10.1016/j.clbc.2025.04.015_bib0012
  article-title: Prognosis of squamous cell carcinoma of the breast by biological subtypes and the efficacy of radiotherapy: the Japanese breast cancer registry analysis
  publication-title: Journal of Clinical Oncology
  doi: 10.1200/JCO.2023.41.16_suppl.561
– volume: 98
  year: 2019
  ident: 10.1016/j.clbc.2025.04.015_bib0024
  article-title: Change of HER2 status during disease recurrence predicts good prognosis for primary squamous cell carcinoma of the breast: a case report
  publication-title: Medicine (Baltimore)
– volume: 37
  start-page: 867
  year: 2013
  ident: 10.1016/j.clbc.2025.04.015_bib0015
  article-title: Primary squamous cell carcinoma of the breast: predictors of locoregional recurrence and overall survival
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0b013e3182877569
– volume: 3
  start-page: 367
  year: 1996
  ident: 10.1016/j.clbc.2025.04.015_bib0020
  article-title: Squamous cell carcinoma of the breast: a clinical approach
  publication-title: Ann Surg Oncol
  doi: 10.1007/BF02305666
– volume: 19
  start-page: 26
  year: 2019
  ident: 10.1016/j.clbc.2025.04.015_bib0009
  article-title: Clinicopathological features, treatment patterns, and prognosis of squamous cell carcinoma of the breast: an NCDB analysis
  publication-title: BMC Cancer
  doi: 10.1186/s12885-018-5212-x
– volume: 21
  start-page: 44
  year: 2020
  ident: 10.1016/j.clbc.2025.04.015_bib0028
  article-title: Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(19)30689-8
– volume: 164
  start-page: 201
  year: 2017
  ident: 10.1016/j.clbc.2025.04.015_bib0002
  article-title: Squamous cell carcinoma of the breast in the United States: incidence, demographics, tumor characteristics, and survival
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-017-4251-3
– volume: 67
  start-page: 94
  year: 2017
  ident: 10.1016/j.clbc.2025.04.015_bib0013
  article-title: Breast implant capsule-associated squamous cell carcinoma: a report of 2 cases
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2017.07.011
– volume: 59
  start-page: 199
  year: 1995
  ident: 10.1016/j.clbc.2025.04.015_bib0021
  article-title: Primary squamous cell carcinoma of the breast: sensitivity to cisplatinum-based chemotherapy
  publication-title: J Surg Oncol
  doi: 10.1002/jso.2930590313
– volume: 29
  start-page: 386
  year: 2003
  ident: 10.1016/j.clbc.2025.04.015_bib0018
  article-title: Squamous cell carcinoma of the breast: clinico-pathologic implications and outcome
  publication-title: Eur J Surg Oncol
  doi: 10.1053/ejso.2002.1422
– volume: 149
  start-page: 133
  year: 2015
  ident: 10.1016/j.clbc.2025.04.015_bib0022
  article-title: Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-014-3224-z
– volume: 354
  start-page: 567
  year: 2006
  ident: 10.1016/j.clbc.2025.04.015_bib0025
  article-title: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa053422
– volume: 33
  start-page: 143
  year: 2019
  ident: 10.1016/j.clbc.2025.04.015_bib0005
  article-title: [Squamous cell carcinoma of the breast: a case study conducted in Mauritania]
  publication-title: Pan Afr Med J
– volume: 159
  year: 2021
  ident: 10.1016/j.clbc.2025.04.015_bib0029
  article-title: Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2021.103223
– volume: 24
  start-page: 733
  year: 2017
  ident: 10.1016/j.clbc.2025.04.015_bib0016
  article-title: Cytogenetic analysis of metaplastic squamous cell carcinoma of the breast inter- and intratumoral heterogeneity
  publication-title: Breast Cancer
  doi: 10.1007/s12282-017-0768-x
– volume: 359
  start-page: 1116
  year: 2008
  ident: 10.1016/j.clbc.2025.04.015_bib0026
  article-title: Platinum-based chemotherapy plus cetuximab in head and neck cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0802656
– volume: 180
  start-page: 87
  year: 2020
  ident: 10.1016/j.clbc.2025.04.015_bib0007
  article-title: Squamous cell carcinoma of the breast, are there two entities with distinct prognosis? a series of 39 patients
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-020-05525-5
– volume: 10
  start-page: e3405
  year: 2018
  ident: 10.1016/j.clbc.2025.04.015_bib0014
  article-title: Breast squamous cell carcinoma following breast augmentation
  publication-title: Cureus
– volume: 47
  start-page: 275
  year: 2018
  ident: 10.1016/j.clbc.2025.04.015_bib0019
  article-title: Management and prognosis of pure primary squamous cell carcinoma of the breast
  publication-title: J Gynecol Obstet Hum Reprod
  doi: 10.1016/j.jogoh.2018.06.007
– volume: 202
  start-page: 465
  year: 2006
  ident: 10.1016/j.clbc.2025.04.015_bib0001
  article-title: Pure primary squamous cell carcinoma of the breast: a rare presentation and clinicopathologic comparison with usual ductal carcinoma of the breast
  publication-title: Pathol Res Pract
  doi: 10.1016/j.prp.2006.01.006
– volume: 7
  start-page: 10684
  year: 2016
  ident: 10.1016/j.clbc.2025.04.015_bib0010
  article-title: Effect of postoperative radiotherapy for squamous cell cancer of the breast in a surveillance epidemiology and end results population-based study
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.7222
– volume: 75
  start-page: 914
  year: 2009
  ident: 10.1016/j.clbc.2025.04.015_bib0017
  article-title: Squamous cell carcinoma of the breast: a review of 177 cases
  publication-title: Am Surg
  doi: 10.1177/000313480907501010
– volume: 15
  start-page: 1057
  year: 2019
  ident: 10.1016/j.clbc.2025.04.015_bib0004
  article-title: Squamous cell carcinoma of the breast: a retrospective study
  publication-title: J Cancer Res Ther
  doi: 10.4103/jcrt.JCRT_303_17
– volume: 31
  start-page: 172
  year: 2014
  ident: 10.1016/j.clbc.2025.04.015_bib0023
  article-title: Co-expression of EGFR and CK5/6 in primary squamous cell carcinoma of the breast
  publication-title: Med Oncol
  doi: 10.1007/s12032-014-0172-8
– volume: 41
  start-page: 328
  year: 2011
  ident: 10.1016/j.clbc.2025.04.015_bib0008
  article-title: Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast
  publication-title: Surg Today
  doi: 10.1007/s00595-009-4276-2
– volume: 379
  start-page: 2108
  year: 2018
  ident: 10.1016/j.clbc.2025.04.015_bib0027
  article-title: Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1809615
– volume: 28
  start-page: 776
  year: 2018
  ident: 10.1016/j.clbc.2025.04.015_bib0006
  article-title: Squamous cell carcinoma of the breast
  publication-title: J Coll Physicians Surg Pak
SSID ssj0026310
Score 2.408646
Snippet To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype....
To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage e739
SubjectTerms Adult
Aged
Breast cancer
Breast Neoplasms - metabolism
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Carcinoma, Ductal, Breast - metabolism
Carcinoma, Ductal, Breast - mortality
Carcinoma, Ductal, Breast - pathology
Carcinoma, Squamous Cell - metabolism
Carcinoma, Squamous Cell - mortality
Carcinoma, Squamous Cell - pathology
Female
Humans
Incidence
Kaplan-Meier Estimate
Middle Aged
Prognosis
Propensity Score
Propensity score matching
Rare tumor
Receptor subtype
Receptor, ErbB-2 - metabolism
Receptors, Estrogen - metabolism
Receptors, Progesterone - metabolism
SEER Program - statistics & numerical data
Survival Rate
Triple Negative Breast Neoplasms - epidemiology
Triple Negative Breast Neoplasms - mortality
Triple Negative Breast Neoplasms - pathology
Title Prognostic Analysis of Hormone Receptors and HER2 in Breast Squamous Cell Carcinoma: A Matched Study Using the SEER Database
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1526820925001065
https://dx.doi.org/10.1016/j.clbc.2025.04.015
https://www.ncbi.nlm.nih.gov/pubmed/40450500
https://www.proquest.com/docview/3215982374
Volume 25
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhgdJLafrcNglT6K2469Uz6m2z3eC2JJRsA7kJSZZhw9a7Dc6hUPrbO-PHQqAPKPhiW8JCI898I30zw9hrK1UItGsTpUmZjOizWi1DNqlkpY6Flnlqs32e6-JSfrxSVztsNsTCEK2y1_2dTm-1df9k3M_meLNcjhcTylTCc4tGnBwbCjSX0tAqf_tzS_PgWnQZCbBxRq37wJmO4xVXgdIYctWmO6XSuL83Tn8Cn60ROn3IHvToEabdAPfZTqofsXtn_fn4Y_bj882amHP4GoZ0I7CuoEBkuq4TIEhMG6qvA74uoZhfcFjWcELE9AYW3249bQTALK1WMKMiQ_X6q38HUzjzJNwSiHX4HVqaASByhMV8fgHvfePJGD5hl6fzL7Mi6-srZJEb1WTCV8bnQnkEEVGq0lC4tsKrMiJOfBTSVlYE9DC1tiH6FKzh2k8kj1x6w8VTtlvj4J8zKCsdDX5LhJik0OQnmdweRxGEL_MyjNibYWLdpkuj4QZ-2bUjMTgSg8ulQzGMmBjm3g0BoqjSHGr5v_ZS2153ltA_-70axOvw36IDE18nnG4nEA9ZyuYjR-xZJ_ft6CVi4RxX3ov__OpLdp_uOi7hAdttbm7TIeKbJhy1C_iI7U0_fCrOfwE3u_Z6
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LaxsxEBapA20voc_U6WsKvZXF69Ur6s11HTZNbEqcQG5C0mrBxV27YXMo9Md3Zh-GQh9Q2NNqB4kZ7cw30ugTY2-NkN7Tqk0QOiYiYM5qlPDJuBSlPOZKpLFh-1yo_Ep8upbXe2zan4WhssrO97c-vfHW3ZtRp83RdrUaLcfEVJKlBoM4JTbyDtsndio5YPuT07N8scu7FG9JCfD7hAS6szNtmVdYe2IyzGTDeEq34_4-Pv0JfzZx6OQBO-gAJEzaMT5ke7F6xO7Ouy3yx-zH55sNFc9hM_SMI7ApIUdwuqkiIE6MW7piB1xVQD67yGBVwQeqTa9h-e3W0VoATON6DVO6Z6jafHXvYQJzR_YtgAoPv0NTaQAIHmE5m13AR1c7iodP2NXJ7HKaJ90VC0nItKwT7krtUi4d4oggZKHpxLbEp9Q8jF3gwpSGe0wylTI-uOiNzpQbiyxkwumMP2WDCgf_jEFRqqCxL-5DFFxRqqRTcxy4565ICz9k73rF2m3LpGH7ErMvlsxgyQw2FRbNMGS8173tz4iiV7Po6P8qJXdSv8yif8q96c1r8feiPRNXRVS35QiJDBH6iCE7bO2-G71AOJzi5Dv6z15fs3v55fzcnp8uzp6z-9TSlha-YIP65ja-RLhT-1fddP4Jr9z5Kw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+Analysis+of+Hormone+Receptors+and+HER2+in+Breast+Squamous+Cell+Carcinoma%3A+A+Matched+Study+Using+the+SEER+Database&rft.jtitle=Clinical+breast+cancer&rft.au=Wang%2C+Miao&rft.au=Hu%2C+Kehua&rft.au=Gao%2C+Yanping&rft.au=Guo%2C+Xiaowan&rft.date=2025-08-01&rft.pub=Elsevier+Inc&rft.issn=1526-8209&rft.volume=25&rft.issue=6&rft.spage=e739&rft.epage=e749.e2&rft_id=info:doi/10.1016%2Fj.clbc.2025.04.015&rft.externalDocID=S1526820925001065
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1526-8209&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1526-8209&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1526-8209&client=summon